Order Article Reprints

Meineke R, Stelz S, Busch M, Werlein C, Kühnel M, Jonigk D, Rimmelzwaan GF, Elbahesh H. FDA-Approved Inhibitors of RTK/Raf Signaling Potently Impair Multiple Steps of In Vitro and Ex Vivo Influenza A Virus Infections. Viruses. 2022; 14(9):2058. https://doi.org/10.3390/v14092058

Meineke, Robert, Sonja Stelz, Maximilian Busch, Christopher Werlein, Mark Kühnel, Danny Jonigk, Guus F. Rimmelzwaan, and Husni Elbahesh. 2022. "FDA-Approved Inhibitors of RTK/Raf Signaling Potently Impair Multiple Steps of In Vitro and Ex Vivo Influenza A Virus Infections" Viruses 14, no. 9: 2058. https://doi.org/10.3390/v14092058

Meineke, R., Stelz, S., Busch, M., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2022). FDA-Approved Inhibitors of RTK/Raf Signaling Potently Impair Multiple Steps of In Vitro and Ex Vivo Influenza A Virus Infections. Viruses, 14(9), 2058. https://doi.org/10.3390/v14092058